Study wrapper · #322
FDA-approved drugs as potential covalent inhibitors of key SARS-CoV-2 proteins: an in silico approach.
Editor's note
This is a computer-modelling (in silico) screen, and bremelanotide surfaces only as one of several existing drugs that docking software ranked as a possible binder to a SARS-CoV-2 replication enzyme (RdRp). No cells, animals, or people were involved — the work is entirely simulated binding and molecular-dynamics calculations. That places it at the very bottom of the evidence hierarchy for any antiviral claim: computational hits frequently fail when tested in the lab. The authors themselves stress that experimental and preclinical validation is required before any clinical consideration. For bremelanotide specifically, there is no biological, let alone clinical, evidence here of antiviral activity, and nothing about this repurposing hypothesis relates to its actual approved use or its melanocortin mechanism. Treat it as a hypothesis-generating computational exercise only. These are preclinical, in silico findings; experimental and human data would be needed before any conclusions could be drawn.
Plain-language abstract
During the COVID-19 pandemic, researchers looked for existing approved drugs that might be repurposed against the virus. In this study they used computer simulations — not lab experiments — to test how well a library of FDA-approved drugs might latch onto four proteins important for the virus's life cycle, including an enzyme the virus uses to copy its genetic material. The methods were entirely computational: docking software that predicts binding, followed by simulations of how stable those predicted bonds would be. Several drugs came up as candidate binders for different targets; bremelanotide was among the compounds flagged as a possible binder to the virus's copying enzyme, alongside drugs such as lanreotide, histrelin, and leuprolide. The authors are explicit that these are only computer predictions and that laboratory and preclinical testing would be needed to confirm whether any of these drugs actually blocks the virus and is safe for that purpose. In short, this is an early computational screening idea, and it does not show that bremelanotide has any effect on the coronavirus.